NBI-1065890

DRUG2 trials

Sponsors

Neurocrine Biosciences Inc., Neurocrine Biosciences

Conditions

Tardive Dyskinesia

Phase 2

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

RecruitingNCT07365462

Neurocrine BiosciencesTardive Dyskinesia

Start: 2026-02-06End: 2027-03-01Target: 100Updated: 2026-06-23

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Not yet recruitingCTIS2025-524104-30-00

Neurocrine Biosciences Inc.Tardive Dyskinesia

Target: 5Updated: 2026-09-08